{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:46:41Z","timestamp":1790531201036,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.14283\/jpad.2021.21","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:01:20Z","timestamp":1621296080000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU\/US CTAD Task Force"],"prefix":"10.1016","volume":"8","author":[{"given":"P.S.","family":"Aisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.14283\/jpad.2021.21_bib1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41582-020-00414-3","article-title":"The search for Alzheimer disease therapeutics \u2014 same targets, better trials?","volume":"16","author":"Rafii","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.14283\/jpad.2021.21_bib2","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"10250","key":"10.14283\/jpad.2021.21_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(20)31787-6","article-title":"COVID-19 and readjusting clinical trials","volume":"396","author":"van Dorn","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"10.14283\/jpad.2021.21_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.14283\/jpad.2021.21_bib5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.14283\/jpad.2021.21_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S1041610297004870","article-title":"Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type","volume":"9","author":"Morris","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"10.14283\/jpad.2021.21_bib7","author":"Strobel"},{"key":"10.14283\/jpad.2021.21_bib8","author":"Strobel"},{"key":"10.14283\/jpad.2021.21_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2021.21_bib10","article-title":"Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation","author":"Farrell","year":"2020","journal-title":"Neurology"},{"key":"10.14283\/jpad.2021.21_bib11","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/brain\/aws125","article-title":"Regional dynamics of amyloid-\u03b2 deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study","volume":"135","author":"Villain","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.14283\/jpad.2021.21_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(15)00323-3","article-title":"Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study","volume":"15","author":"Jack","year":"2016","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.14283\/jpad.2021.21_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14283\/jpad.2019.14","article-title":"Anti-Tau Trials for Alzheimer's Disease: A Report from the EU\/US\/CTAD Task Force","volume":"6","author":"Cummings","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2021.21_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2021.21_bib15","author":"Mullard"},{"issue":"1","key":"10.14283\/jpad.2021.21_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"577","key":"10.14283\/jpad.2021.21_bib17","volume":"13","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.14283\/jpad.2021.21_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14283\/jpad.2019.46","article-title":"The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0","volume":"7","author":"Ritchie","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2021.21_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.14283\/jpad.2019.41","article-title":"Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS","volume":"7","author":"Rosenberg","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.14283\/jpad.2021.21_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14283\/jpad.2020.45","article-title":"The Trial-Ready Cohort for Preclinical\/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview","volume":"7","author":"Aisen","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.14283\/jpad.2021.21_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14283\/jpad.2020.46","article-title":"Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD)","volume":"7","author":"Walter","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.14283\/jpad.2021.21_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.14283\/jpad.2020.47","article-title":"The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years","volume":"7","author":"Walter","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.14283\/jpad.2021.21_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.14283\/jpad.2020.48","article-title":"TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology","volume":"7","author":"Jimenez-Maggiora","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.14283\/jpad.2021.21_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.14283\/jpad.2020.44","article-title":"Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials","volume":"7","author":"Langford","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"10.14283\/jpad.2021.21_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.14283\/jpad.2021.21_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","article-title":"An overview of platform trials with a checklist for clinical readers","volume":"125","author":"Park","year":"2020","journal-title":"Journal of Clinical Epidemiology"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:13:53Z","timestamp":1737321233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724005223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2274580724005223"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2021.21","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU\/US CTAD Task Force","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2021.21","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}